secwatch / observer
8-K filed July 5, 2023, 7:59 PM ET ticker AEON CIK 0001837607
M&A confidence high sentiment neutral materiality 0.75

Priveterra (PMGM) stockholders approve AEON Biopharma merger; 1.68M shares redeemed

AEON Biopharma, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AEON Biopharma, Inc. shareholders approved Adoption of the Business Combination Proposal at the 2023-07-03 meeting.

Proposal
merger approval
Outcome
passed
Meeting
2023-07-03
Exact text from the filing
Proposal 1: Adoption of the Business Combination Proposal Priveterra’s stockholders, by ordinary resolution, (i) adopted and approved the Business Combination Agreement, dated as of December 12, 2022 (as amended or modified from time to time, the “ Business Combination Agreement ”), by and among Priveterra Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Priveterra (“ Merger Sub ”), and AEON Biopharma, Inc., a Delaware corporation (“ AEON ”), pursuant to which Merger Sub will merge with and into AEON, with AEON surviving the merger as a wholly-owned subsidiary of Priveterra, on the terms and subject to the conditions set forth therein; (ii) approved such merger and the other transactions contemplated by the Business Combination Agreement; and (iii) adopted and approved each document ancillary to the Business Combination Agreement to which Priveterra is a party and all transactions contemplated therein. The following were the tabulated votes “For” and “Against” th
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AEON Biopharma, Inc. shareholders approved Adoption of the Advisory Charter Proposal A (corporate name change) at the 2023-07-03 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-07-03
Exact text from the filing
Proposal 3A: Adoption of the Advisory Charter Proposal A Priveterra’s stockholders approved by non-binding, advisory resolution the provisions in the Proposed Charter changing the corporate name of Priveterra to “AEON Biopharma, Inc.” at and from the time of the Business Combination. The following were the tabulated votes “For” and “Against” this proposal as well as the number of “Abstentions” and “Broker Non-Votes”: FOR AGAINST ABSTAIN BROKER NON-VOTE 8,189,816 239,010 0 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AEON Biopharma, Inc. shareholders approved Adoption of the Charter Amendment Proposal at the 2023-07-03 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2023-07-03
Exact text from the filing
Proposal 2: Adoption of the Charter Amendment Proposal Priveterra’s stockholders approved by ordinary resolution (including of each class entitled to vote thereon) that the second amended and restated certificate of incorporation and bylaws of Priveterra be amended and restated by the proposed third amended and restated certificate of incorporation for new AEON (the “ Proposed Charter ,” a copy of which is attached to the Proxy Statement as Annex B), and amended bylaws (a copy of which is attached to the Proxy Statement as Annex C), for New AEON, which will be in effect upon the closing of the Business Combination (the “ Closing ”). The following were the tabulated votes “For” and “Against” this proposal as well as the number of “Abstentions” and “Broker Non-Votes”: Combined Common FOR AGAINST ABSTAIN BROKER NON-VOTE 8,189,816 239,010 0 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AEON Biopharma, Inc. shareholders approved Adoption of the Advisory Charter Amendment Proposal C (increase authorized preferred shares) at the 2023-07-03 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-07-03
Exact text from the filing
Proposal 3C: Adoption of the Advisory Charter Amendment Proposal C Priveterra’s stockholders approved by non-binding, advisory resolution the provisions in the Proposed Charter authorizing an increase in the authorized shares of preferred stock that New AEON’s board of directors could issue to 1,000,000 shares. The following were the tabulated votes “For” and “Against” this proposal as well as the number of “Abstentions” and “Broker Non-Votes”: FOR AGAINST ABSTAIN BROKER NON-VOTE 7,753,080 675,746 0 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AEON Biopharma, Inc. shareholders approved Adoption of the Advisory Charter Amendment Proposal D (classified board and removal provisions) at the 2023-07-03 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-07-03
Exact text from the filing
Proposal 3D: Adoption of the Advisory Charter Amendment Proposal D Priveterra’ stockholders approved by non-binding, advisory resolution the provisions in the Proposed Charter dividing the board of directors into three classes following the Business Combination, with the directors serving staggered terms until their respective successors are duly elected and qualified, or until their earlier resignation, death, disqualification or removal and providing that the directors may only be removed for cause and by affirmative vote of 662⁄3% of New AEON’s then-outstanding shares of capital stock entitled to vote generally in the election of directors. The following were the tabulated votes “For” and “Against” this proposal as well as the number of “Abstentions” and “Broker Non-Votes”: FOR AGAINST ABSTAIN BROKER NON-VOTE 7,753,080 675,746 0 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AEON Biopharma, Inc. shareholders approved Adoption of the Advisory Charter Proposal B (increase authorized common shares) at the 2023-07-03 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-07-03
Exact text from the filing
Proposal 3B: Adoption of the Advisory Charter Proposal B Priveterra’s stockholders approved by non-binding, advisory resolution the provisions in the Proposed Charter authorizing an increase in the authorized shares of common stock of New AEON to 500,000,000 shares. The following were the tabulated votes “For” and “Against” this proposal as well as the number of “Abstentions” and “Broker Non-Votes”: FOR AGAINST ABSTAIN BROKER NON-VOTE 8,189,316 239,510 0 0
View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-23-078184
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.